FADS1 and renal carcinoma: Treatment with D5D-IN-326 significantly inhibits the conversion of dihomo-γ-linolenic acid (DGLA), the direct substrate of FADS1, into arachidonic acid (AA), as indicated by the reduced AA/DLGA ratio in the renal cancer cell line 786-o and A498 at 48 h and 96 h (Supplementary Figure 1).